Advertisement

Topics

Merck’s Letermovir, an Investigational Antiviral Medicine for Prevention of Cytomegalovirus (CMV) Infection in Bone Marrow Transplant Recipients, Highly Effective Through Week 24 Post-Transplant in Pivotal Phase 3 Study

12:30 EST 26 Feb 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Letermovir Prophylaxis Associated with Lower All-Cause Mortality Through Week 24 Post-Transplant Company Plans to Submit New Drug Applications for Letermovir in U.S. and EU in 2017 Merck & Co., Inc. (NYSE...

Other Sources for this Article

Merck
Media:
Pam Eisele, 267-305-3558
Robert Consalvo, 908-236-1127
or
Investors:
Teri Loxam, 908-740-1986
Amy Klug, 908-740-1898

NEXT ARTICLE

More From BioPortfolio on "Merck’s Letermovir, an Investigational Antiviral Medicine for Prevention of Cytomegalovirus (CMV) Infection in Bone Marrow Transplant Recipients, Highly Effective Through Week 24 Post-Transplant in Pivotal Phase 3 Study"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Transplantation
Organ transplantation is the moving of an organ from one body to another or from a donor site to another location on the patient's own body, for the purpose of replacing the recipient's damaged or absent organ. The emerging field of regenerative ...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Merck and Co
Merck & Co is the 7th largest pharmaceutical company in the world based on annual sales, which reached $25,236m in 2009. They have developed 14 vaccines and over 40 prescription products in the major therapeutic areas of cardiovascular disease, respi...